Report

The liposome drug delivery market is expected to register a CAGR of 8.5% during the forecast period of the study.

COVID-19 impacted the liposome drug delivery market as various R&D activities involving liposome drug delivery were postponed around the world by the respective government of the countries. However, the importance of liposomes in drug delivery was realized soon and intensive research started on the liposome drug delivery system for the treatment of COVID-19 which propelled the market growth in the later phase of the pandemic. For instance, according to the research study published in the Asian Journal of Pharmaceutical Sciences in November 2021, the researchers developed lyophilized remdesivir liposomes (Rdv-lips), which could be reconstituted as a liposomal aerosol for pulmonary delivery to improve the in vivo behavior of existing remdesivir cyclodextrin conclusion compound (Rdv-cyc) injections and liposome encapsulation endowed remdesivir with much higher solubility and better biocompatibility, and thus, increased the efficacy of the drug. The market is growing in the current scenario because the companies are still engaged in the development of therapeutics against COVID-19, in which liposome-based drugs or vaccines can play a vital role.

The major factor driving the growth of the liposome drug delivery market is the increasing demand for effective and efficient therapeutics since liposome-based drug delivery method offers certain advantages over other delivery systems. For instance, according to the research study published in Molecules Journal in February 2022, liposomes have better properties than standard drug delivery methods, such as site-targeting, prolonged or controlled release, drug protection from degradation and clearance, higher therapeutic effects, and lesser toxic side effects.

Also, the application of liposomes to assist drug delivery has shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving the biodistribution of compounds to target sites in vivo. This enables the effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes are an appealing delivery system due to their adaptable physicochemical and biophysical properties, which allow for easy manipulation to address various delivery concerns. Hence, they are the preferred choice of drug manufacturers.

Furthermore, with the increasing prevalence of chronic diseases such as cancer, diabetes, fungal infections, and others around the world, the demand for effective therapeutics is increasing, which is expected to fuel the growth of the liposome drug delivery market. For instance, according to the December 2021 update of the International Diabetes Federation (IDF), about 537 million adults of age 20 to 79 years were living with diabetes around the world in 2021, and this number is estimated to reach 643 million by 2030 and 783 million by 2045. The projected rise in the number of diabetes cases globally is expected to boost demand for liposomal diabetes therapeutics to increase its efficacy and reduce the toxicity and hence, drive growth of the studied market.

In addition, the increasing advancement in the liposomal drug delivery method with the new investments in the area along with product launches, acquisitions, and collaborations by the market players is further expected to boost the growth of the liposome drug delivery market. For instance, in October 2021, Evonik Health Care, an integrated contract development and manufacturing organization (CDMO) that offers excipients, formulation technologies, and clinical and commercial manufacturing, launched a new version of its established LIPEX liposome extruder. LIPEX Flow meets the market need for more efficient, next-generation high-pressure extruders to produce drug products requiring conventional liposomal drug delivery, including drugs for oncology, vaccines, and other applications.

Therefore, owing to the above-mentioned factors, the studied market is expected to experience significant growth during the study period. However, stringent regulatory policies and adverse effects associated with drug delivery are expected to restrain the growth of the liposome drug delivery market during the forecast period of the study.

Liposome Drug Delivery Market Trends

Cancer Therapeutics are Expected to Account for the Largest Market Share During the Forecast Period

Cancer therapeutics are expected to hold a significant share due to the high prevalence of cancer globally and the rising demand for advanced therapeutics. For instance, as per the Australian Institute of Health and Welfare (AIHW) 2022 report, a total of 162,000 new cancer cases were diagnosed in Australia in 2022. Also, as per Canadian Medical Association Journal, May 2022 report, 28,600 new breast cancer were diagnosed in Canada in 2022. The high burden of cancer globally is expected to propel the segment's growth during the forecast period.

Furthermore, according to the research study published in Nanoscale Research Letters in May 2021, liposomes' high flexibility and capacity for chemical modification by conjugating diverse polymers, ligands, and molecules are a big positive for liposomes in cancer therapeutics, and it increases their pharmacological merits and boosts anticancer treatment effectiveness. Further, as per the same source, liposomes can improve the sensitivity, specificity, and persistence of anti-malignant cell agents in the body, and thus, liposomes are used widely in cancer therapeutics. Therefore, with the rising research studies and advantages offered by liposomes in cancer therapeutics, its demand is expected to witness growth during the forecast period.

Therefore, due to the high prevalence of cancer, the advantages of liposome drug delivery methods over others, the cancer therapeutics segment is expected to hold a major share in the liposome drug delivery market during the forecast period of the study.

North America is Expected to Hold a Significant Share in the Market over the Forecast Period

North America is expected to dominate the liposome drug delivery market due to the high prevalence of chronic diseases in the region, the increasing geriatric population, and the launches of innovative products by the market players.

The high burden of chronic diseases in the region is expected to propel the demand for therapeutics, which is expected to drive growth in the North American region. For instance, according to the CDC's 2022 update, the percentage of coronary heart disease for adults aged 18 and over in the United States increased to 4.9% in 2021 as compared to 4.6% in the previous years. Additionally, according to the American Cancer Society statistics of 2023, around 1.9 million new cancer cases are predicted to be diagnosed in the United States in 2023. Liposomes improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Therefore, the demand for liposome drug delivery is rising for CVD and cancer therapeutics.

Furthermore, the rising government funding for research of various diseases in the United States also plays a crucial role in the growth of the market in the region. For instance, the allocated budget for the National Cancer Institute (United States) for FY 2022 was USD 6.9 billion, which was USD 353 million net increase over FY 2021. Thus, the high spending for R&D in the United States is expected to significantly propel the market in the region during the forecast period.

Liposome Drug Delivery Industry Overview

The liposome drug delivery market is highly competitive with the presence of several players in the market who are engaged in the development of drugs. Also, the companies in the area are continuously enhancing their product offering through new launches, collaborations, partnerships, mergers, and acquisitions which are further expected to increase the competition in the studied market. Some of the key players in the liposome drug delivery market are Gilead Sciences, Inc., Pacira BioSciences, Inc., Luye Pharma Group, Johnson and Johnson, and Ipsen Biopharmaceuticals, Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support